

Research & Reviews: Journal of Medical and Health Sciences

Stem Cell Research Therapy for Neurodegenerative Disorders-In What Way to Make it Work

Nisha Dhama^{1*}, Punit Pal², Sunil Kumar Singh², Swati Srabani Nayak³

¹Department of Biotechnology, Meerut Institute of Engineering & Technology, Meerut, U.P, India

²Department of Biosciences and Technology, VIT University, Vellore, Tamil Nadu, India

³Department of Biotechnology, Fakir Mohan University, Balasore, Odisha, India

Review Article

Received date: 04/30/2015

Accepted date: 05/04/2015

Published date: 05/11/2015

*For Correspondence

Nisha Dhama, Department of Biotechnology,
Meerut Institute of Engineering & Technology,
Meerut, U.P, India, Tel: +91 8897465898;

E-mail: nishadhama1@gmail.com

KEYWORDS: Neurodegenerative disorders; Stem cells; Parkinson's disease; Dopaminergic neurons; Stroke; Neurons

ABSTRACT

Late advance demonstrates that neurons suitable for transplantation can be produced from undeveloped cells in society, and that the grown-up cerebrum creates new neurons from its own undifferentiated organisms because of damage. These discoveries raise trust in the improvement of foundational microorganism treatments in human neurodegenerative issue. Before clinical trials are launched, we have to know a great deal all the more about how to control undifferentiated cell expansion and separation into particular phenotypes, impel their coordination into existing neural and synaptic circuits, and streamline practical recuperation in creature models nearly looking like the human infection.

INTRODUCTION

Stem cells are juvenile cells with delayed self-replenishment limit and, contingent upon their beginning, capacity to separate into various cell sorts or all cells of the body. Transplantation of undifferentiated cells or their subsidiaries, and assembly of endogenous foundational microorganisms inside the grown-up cerebrum, have been proposed as future treatments for neurodegenerative sicknesses ^[1]. It may appear to be unlikely, however, to instigate utilitarian recuperation by supplanting cells lost through malady, considering the multifaceted nature of human mind structure and capacity ^[2]. Studies in creature models have in any case exhibited that neuronal substitution and incomplete reproduction of harmed neuronal hardware is conceivable. There is likewise proving from clinical trials that cell substitution in the unhealthy human mind can prompt symptomatic help ^[3].

Here we audit the logical premise of immature microorganism treatments and examine their prospects in Parkinson's infection, stroke. In each of these neurodegenerative ailments, an alternate range of cell sorts is influenced; consequently, diverse sorts of neurons are needed for substitution ^[4]. We contend that long haul survival of new, practically incorporated neurons is the fundamental objective to attain to greatest symptomatic help through foundational microorganism treatment. Undeveloped cell transplantation might likewise prompt clinically important changes through different components too ^[5-8].

How Stem cell therapies work in patients having Parkinson's disease?

The fundamental pathology in Parkinson's infection (PD) is a degeneration of nigro striatal dopaminergic neurons. Studies in patients with PD after intra striatal transplantation of human fetal mesencephalic tissue, rich in post mitotic dopaminergic neurons, have given verification of rule that neuronal substitution can work in the human cerebrum ^[8-11]. The joined neurons survive and re-innervate the striatum the length of 10 years notwithstanding a continuous infection process, which devastates

Research & Reviews: Journal of Medical and Health Sciences

the quiet's own dopaminergic neurons^[12]. The unions have the capacity to standardize striatal dopamine discharge and to switch the debilitation of cortical enactment basic Akinesia^[13-16]. In this manner, united dopaminergic neurons can get to be practically coordinated into neuronal hardware in the cerebrum. A few open-name trials have reported clinical advantage. A few patients have possessed the capacity to withdraw from L-dopa treatment for quite a long while and resume an autonomous life^[17-22].

Two late sham surgery-controlled trials demonstrated just unassuming change, which represents that present cell substitution systems are a long way from ideal. The poor response in one study could be clarified by uniquely less surviving united dopaminergic neurons as contrasted and that in open-mark trials. In the other study, patients were all the more extremely handicapped at the season of transplantation, demonstrating far reaching degenerative changes. No or fleeting immunosuppression was given in these studies, which may be important to dodge insusceptible responses creating useless unions^[12,15,17,21-26].

Dyskinesias can grow after transplantation and get to be troublesome in 7–15% of united patients. This antagonistic impact is not because of dopaminergic abundance. It might be brought about by uneven and sketchy re-innervation, offering ascent to low or middle of the road measures of striatal dopamine, or by interminable provocative and resistant reactions around the union^[27-32]. Then again, unite prompted dyskinesias could be clarified by unfavorable organization of the union concerning the overwhelming kind of mesencephalic dopaminergic neurons from the substantia nigra or ventral tegmental range and the extent of cells that are not dopaminergic^[32-41].

How Neurons from stem cells work for Parkinson's disease?

It is impossible that transplantation of human fetal mesencephalic tissue will get to be routine treatment for persons with PD due to issues with tissue accessibility and an excessive amount of variety in practical result. Foundational microorganism innovation can possibly create expansive quantities of dopaminergic neurons in institutionalized arrangements^[15,18-22,28]. On the premise of results with fetal transplants in creatures and people, it is conceivable to recognize an arrangement of necessities that presumably additionally need to be satisfied by stem cell-derived cells to impel checked clinical change: (i) the cells ought to discharge dopamine in a controlled way and ought to demonstrate the sub-atomic, morphological and electrophysiological properties of substantia nigra neurons; (ii) the cells must have the capacity to switch in creatures those engine shortfalls that take after the side effects in persons with PD; (iii) the yield of cells ought to consider no less than 100,000 united dopaminergic neurons to make due over the long haul in every human putamen; (iv) the joined dopaminergic neurons ought to re-build a thick terminal system all through the striatum; (v) the unions must get to be practically coordinated into host neural circuitries^[15,19,23,25,27,41-52].

Just 5–10% of cells in fetal mesencephalic unions are dopaminergic neurons. It is not yet known whether it is ideal to embed an unadulterated populace of dopaminergic neurons or whether the union ought to additionally contain a particular synthesis of other neuron sorts and glial cells to actuate most extreme symptomatic help. Late studies demonstrate a significant part of astrocytes in indicating neuronal phenotypes amid embryonic improvement, recommending that glial cells are imperative for destiny choice by NSCs and forerunners before or after transplantation^[53-57].

How to create a stem-cell therapy for Parkinson's disease?

A clinically focused cell treatment must give focal points over current medications to PD. Cell-based methodologies ought to actuate enduring, significant upgrades of portability and concealment of dyskinesias. On the other hand, the new cells ought to enhance side effects that are impervious to different medications, for example, parity issues^[58]. Enhancements after fetal unions have not surpassed those found with profound cerebrum incitement, and there is no persuading confirmation for inversion of medication safe indications. Fragmented recuperation could be because of just piece of the striatum having been re innervated. Indeed, even in creatures with great re innervation, nonetheless, upgrades are just incomplete, demonstrating that the ectopic joining position in the striatum may be of critical significance^[59]. Unions embedded in the substantia nigra issue a few upgrades in creatures and have been tried clinically, however they are not ready to reproduce the nigro striatal pathway^[60]. Regardless of the fact that undifferentiated cell innovation can produce expansive quantities of dopaminergic neurons, the advancement of compelling cell treatment for PD will oblige three extra advances^[61-65].

First and foremost, better criteria for selecting the patients suitable for cell treatment must be characterized. Dopaminergic cell treatment will no doubt be fruitful just in those influenced people who show checked symptomatic advantage in light of L-dopa and in whom the principle pathology is a loss of dopaminergic neurons. Weakening indications in PD and related issue are additionally brought on by neurotic changes in non-dopaminergic frameworks^[66].

Second, the transplantation strategy ought to be tweaked concerning the measurements and area of united cells so that

Research & Reviews: Journal of Medical and Health Sciences

the repair of the dopamine framework will be as complete as would be prudent in each tolerant's cerebrum. There is so far no proof that stem cell-derived dopaminergic neurons will actuate more claimed change as contrasted and essential neurons in fetal unions. One preference with undifferentiated cells is the likelihood for controlled hereditary change ^[65,66].

Third, procedures to stay away from antagonistic impacts must be created. New creature models are expected to uncover the pathophysiological instruments of union actuated dyskinesias. The danger for teratoma from ESCs and additionally the outcomes of presenting new qualities in stem cell-derived neurons ought to be precisely assessed. Implantation of mouse ESCs into rodent striatum brought about teratomas in 20% of the creatures. In any case, the danger is decreased if the cells are separated previously in vitro ^[65-70].

How stem cell therapies work for stroke disease?

In stroke, impediment of a cerebral artery prompts central ischemia in a confined CNS locale. Various sorts of neurons and glial cells worsen in stroke. It has not yet been convincingly shown that neuronal substitution prompts symptomatic alleviation in people who have endured strokes ^[71]. In the main reported clinical trial, persons with stroke influencing basal ganglia got inserts of neurons created from the human NT-2 terato carcinoma cell line into the infarcted range ^[72]. Upgrades in some influenced people related with expanded metabolic action at the joining site. This finding could be deciphered as joining capacity yet should reflect aggravation or expanded movement in host neurons. Dissection in one person who had endured a stroke uncovered a populace of united cells communicating a neuronal marker 2 years after surgery ^[73-75].

How Neurons from stem cells work for stroke disease?

Cells from diverse sources have been tried for their capacity to remake the forebrain and enhance work after transplantation in creatures subjected to stroke ^[76]. In spite of the fact that the transplanted cells can survive and part of the way turn around some behavioral shortages, the systems hidden the watched changes are misty and there is little confirmation for neuronal substitution ^[77,78]. By and large, just a couple of united cells survived, and these did not demonstrate the phenotype of the dead neurons. Also, it is obscure whether these cells are practical neurons and create associations with host neurons. Bone marrow-derived cells were likewise depicted to offer ascent to neurons in the stroke-harmed mind. Nonetheless, two late reports challenge this elucidation by exhibiting that combination is in charge of the presence of giver determined neurons after systemic organization of bone marrow cells ^[79-81].

How to create a stem cell therapy for stroke disease?

To repair the stroke-harmed cerebrum may appear to be unreasonable on account of decay and loss of numerous cell sorts. Notwithstanding, even re-foundation of just a small amount of harmed neuronal hardware could have critical ramifications. In the perfect situation, NSCs embedded in the harmed zone will separate in situ into those cells that have passed on ^[81]. This technique obliges that the to a great extent obscure formative instruments teaching undifferentiated cells to separate into particular cell sorts will work additionally in the cerebrum of the influenced person ^[82]. For greatest useful recuperation, transplantation ought to likely be consolidated with incitement of neurogenesis from endogenous NSCs. Neurogenesis happens from NSCs in the human SVZ, and neuronal forerunners are found in human subcortical white matter ^[83].

Satisfactory blood supply will be critical for survival and advancement of the new neurons. Neurogenesis is nearly connected with angiogenesis from endothelial forerunners. Angiogenesis happens in the human mind after stroke however may must be further fortified to expand the yield of surviving new neurons. Organization of vascular endothelial development variable (VEGF) advances SVZ neurogenesis and angiogenesis in the penumbra (area at danger) after stroke. VEGF can likewise guide coordinated relocation of undifferentiated SVZ neural ancestors. For effective repair it might be important to furnish NSCs with a stage so they can re-structure suitable cerebrum structure. In neonatal mice, NSCs seeded on engineered extracellular lattice and embedded into the ischemia-harmed zone created new vascularized parenchyma containing neurons and glia ^[71,75-82].

For building up the neuronal substitution procedure toward clinical application, three distinct errands can be recognized: (i) Proof of guideline ought to be acquired that neurons produced from NSCs can get by in vast numbers in creatures subjected to stroke, move to suitable areas, show morphological and practical properties of those neurons that have passed on and build afferent and efferent synaptic cooperations with neurons that survived the affront. (ii) Behavioral recuperation must be advanced in creature models. Systems to enhance survival, separation and reconciliation of NSCs will require definite information of the regulation of these procedures. (iii) There is a need to characterize which patients are suitable for undifferentiated cell treatment. The event of striatal neurogenesis after stroke centers the enthusiasm on people with basal ganglia infarcts. In the event that

Research & Reviews: Journal of Medical and Health Sciences

undifferentiated cells can likewise produce cortical neurons and repair axonal harm, people with sores in the cerebral cortex may be incorporated ^[83-92].

DISCUSSION

The improvement of stem cell –based treatments for neurodegenerative issue is still at an early stage. Numerous fundamental issues stay to be determined, and we have to advance with alert and keep away from experimentally not well established trials in influenced people. One test now is to recognize sub-atomic determinants of undifferentiated organism expansion to control undesired development and hereditary modifications of ESCs, and in addition to better deal with the extension of NSCs ^[93-96]. We likewise need to know how to example foundational microorganisms to get a more finish collection of different sorts of cells for substitution, and how to actuate powerful practical mix of stem cell–derived neurons into existing neural and synaptic systems. Mechanical advances will be expected to make exact hereditary adjustments of undifferentiated organisms or their descendants that will upgrade their ability for movement, reconciliation and pathway remaking.

The capability of the mind's self-repair systems is practically unexplored. We have to create innovations for hereditary marking of foundational microorganism offspring so we can solidly build where neurogenesis happens and which cell sorts are created after harm. The utilitarian properties of the new neurons and their capacity to shape proper afferent and efferent associations ought to be resolved. We additionally need to recognize, with the guide of genomic and proteomic methodologies, the cell and atomic players that, in a deliberate activity, manage distinctive ventures of neurogenesis. On the premise of this learning, we ought to outline procedures to convey atoms that enhance the yield of new useful neurons and different cells in the harmed zone ^[97-102].

To help in further advance toward the facility, we likewise need to create creature models that nearly impersonate the human ailment. Such models will permit us to evaluate and equalization potential dangers and advantages of immature microorganism treatments before their application in people. Moreover, we have to enhance noninvasive imaging advancements with the goal that we can screen regenerative techniques resulting to stem cell–based methodologies in creatures and humans ^[92-104].

REFERENCES

1. Sarah Abdulmalek, Mansour Suliman, Osman Omer (2015) Possible Neuroprotective Role of Pomegranate Juice in Aluminum Chloride Induced Alzheimer's Like Disease in Mice. *J Alzheimers Dis Parkinsonism* 5: 188.
2. Stefano Pallanti, Anna Marras (2015) Transcranial Magnetic Stimulation in Alzheimer's Disease: A Review of Investigational and Therapeutic Findings. *J Alzheimers Dis Parkinsonism* 5: 187.
3. Tiffany Field (2015) Smell and Taste Dysfunction as Early Markers for Neurodegenerative and Neuropsychiatric Diseases. *J Alzheimers Dis Parkinsonism* 5: 186.
4. Claudia Meyer, Keith Hill, Sophie Hill and Briony Dow (2015) Translating Falls Prevention Knowledge for Community-Dwelling People Living With Dementia: Design Protocol for a Mixed-Method Intervention. *J Alzheimers Dis Parkinsonism* 5: 185.
5. Dennis A Davey (2015) Alzheimer's Disease, Cerebrovascular Disease and Dementia: A Potentially Preventable and Modifiable Syndrome. *J Alzheimers Dis Parkinsonism* 5: 184.
6. Diane Stephenson, Martha Brumfield, Klaus Romero, Janet Woodcock, Issam Zineh, et. al. (2015) Alzheimer's and Parkinson's Diseases Face Common Challenges in Therapeutic Development: Role of the Precompetitive Consortium, Coalition Against Major Diseases. *J Alzheimers Dis Parkinsonism* 5: 183.
7. Manly Sani, Boyo Blossom Hans Idris, Ibrahim BG Bako (2015) Successful Regeneration of CNS Nerve Cells a Possible Bye Bye O Debilitating Effects Of Neurodegenerative Diseases. *J Alzheimers Dis Parkinsonism* 5: 182.
8. Yuri N Utkin, Elena V Kryukova, Victor I Tsetlin (2015) What Animal Models of Parkinsonism Tell us About the Distinct Nicotinic Acetylcholine Receptors Involved in Pathogenesis?. *J Alzheimers Dis Parkinsonism* 5: 181.
9. Gila Bronner (2015) Addressing Sexuality in Dementia: A Challenge for Healthcare Providers. *J Alzheimers Dis Parkinsonism* 5: 180.
10. Lilian Calderoacuten Garciduentildeas, Angeacutelica GoacutenzalezMaciel, Aristo Vojdani, Maricela FrancoLira, Rafael Reynoso Robles, et. al. (2015) The Intestinal Barrier in Air Pollution-Associated Neural Involvement in Mexico City Residents: Mind the Gut, the Evolution of a Changing Paradigm Relevant to Parkinson Disease Risk. *J Alzheimers Dis Parkinsonism* 5: 179.

Research & Reviews: Journal of Medical and Health Sciences

11. Thiyagarajan Devasena, Arul Prakash Francis (2015) Nanotoxicity-Induced Alzheimer Disease and Parkinsonism: Not Further than Diagnosis. *J Alzheimers Dis Parkinsonism* 5: 178.
12. Zhao Y, Dua P, Lukiw WJ (2015) Microbial Sources of Amyloid and Relevance to Amyloidogenesis and Alzheimer's Disease (AD). *J Alzheimers Dis Parkinsonism* 5: 177.
13. Povova Jana, Sery Omar, Tomaskova Hana, Vargova Lydia, Ambroz Petr, et al. (2015) Epidemiology and Genetics of Alzheimer's Disease. *J Alzheimers Dis Parkinsonism* 5: 176.
14. Mark D Miller, Richard K Morycz (2015) Preparing for the Rise in Alzheimers Disease Cases: A Proposal for Training Support Personnel. *J Gerontol Geriatr Res* 4: 195.
15. Knarik Arkun, Ann C Rice, James P Bennett (2015) Effect of Lewy Bodies on Mitochondrial DNA Copy Numbers and Deletion Burden in Parkinson's Disease Substantia nigra Neurons. *J Alzheimers Dis Parkinsonism* 4: 175.
16. Astrid Haram, Erik Hessen, Eirik Auning, Ane Lvli Stav, Bradley Boeve, et al. (2014) Clinical Correlates of RBD in Early Parkinson Disease. *J Alzheimers Dis Parkinsonism* 4: 174.
17. Victoria I Bunik (2014) Benefits of Thiamin (Vitamin B1) Administration in Neurodegenerative Diseases may be Due to Both the Coenzyme and Non-coenzyme Roles of Thiamin. *J Alzheimers Dis Parkinsonism* 4: 173.
18. ALa Park (2014) Is There Anything Special About Intergenerational Approaches to Older People with Dementia? A Review. *J Alzheimers Dis Parkinsonism* 4: 172.
19. Hyun Kim, Aerin Shin, Kang Joon Lee (2015) Differences in C-reactive Protein Level in Patients with Alzheimers Disease and Mild Cognitive Impairment. *J Psychiatry* doi: 10.4172/Psychiatry.1000194
20. David R. Borchelt, Guilian Xu, Lucia Notterpek, Jada Lewis (2014) Proteostasis and Secondary Proteinopathy in Alzheimer's Disease. *J Alzheimers Dis Parkinsonism* 4: 145.
21. Vanessa K Hinson, Amy Delambo, Aaron E Embry, Chris Gregory, Kathryn Gaines, et al. (2014) Forced Exercise for Freezing of Gait in Post STN DBS Parkinson's Disease Patients. *J Alzheimers Dis Parkinsonism* 4: 171.
22. Borroni B, Benussi A, Pilotto A, Gazzina S, Turrone R, et. al. (2014) Diagnosing Progressive Supranuclear Palsy: Role of Biological and Neuroimaging Markers. *J Alzheimers Dis Parkinsonism* 4: 168.
23. Keiko Ikemoto, Katsuji Nishi, Akiyoshi Nishimura (2014) Lectin-Positive Spherical Deposits (SPD) Detected in the Molecular Layer of Hippocampal Dentate Gyrus of Dementia, Down's Syndrome ,and Schizophrenia. *J Alzheimers Dis Parkinsonism* 4: 169.
24. Xu Xin, Tri Budi Rahardjo, ShifuXiao, Eef Hogervorst (2014) The Hopkins Verbal Learning Test and Detection of MCI and Mild Dementia: A Literature Review. *J Alzheimers Dis Parkinsonism* 4: 166.
25. Paul Whitesman (2014) Preliminary Set Theory-Type Analysis of Proteins Associated With Parkinson's Disease. *J Alzheimers Dis Parkinsonism* 4: 170.
26. Raheel Mushtaq, Sheikh Shoib, Tabindah Shah, Sahil Mushtaq (2014) Comparison of Cognitive Symptoms in Subtypes of Alzheimer's disease (AD)-A Study from South East Asia (Kashmir, India). *J Alzheimers Dis Parkinsonism* 4: 167.
27. Roberta Ciuffini, Alfonso Marrelli, Stefano Necozone, Carmine Marini, Alessandra Cavicchio, et al. (2014) Visual Evoked Potentials in Alzheimer's Disease: Electrophysiological Study of the Visual Pathways and Neuropsychological Correlates. *J Alzheimers Dis Parkinsonism* 4: 158.
28. Trent W Nichols (2014) Hyperphosphorylation of Tau Protein in Down's Dementia and Alzheimer's Disease: Methylation and Implications in Prevention and Therapy. *J Alzheimers Dis Parkinsonism* 4: 159.
29. Carrie A Ciro, Dao HD, Michael Anderson, Cynthia A Robinson, Toby Ballou Hamilton, et al. (2014) Improving Daily Life Skills in People with Dementia: Testing the STOMP Intervention Model. *J Alzheimers Dis Parkinsonism* 4: 165.
30. Travis H Turner, Ann Charlotte Granholm, Amy Duppsstadt Delambo, Heather Boger, Guttalu Kumaraswamy, et al. (2014) Epidermal Growth Factor (EGF) is Associated with Memory and Executive Functioning in Progressed Parkinson's Disease. *J Alzheimers Dis Parkinsonism* 4: 164.

Research & Reviews: Journal of Medical and Health Sciences

31. Yellamma K (2014) Silk Protein, Sericin as a Cognitive Enhancer in Alzheimer's Disease. J Alzheimers Dis Parkinsonism 4: 163.
32. Tiwari SC, Soni RM (2014) Alzheimer's Disease Pathology and Oxidative Stress: Possible Therapeutic Options. J Alzheimers Dis Parkinsonism 4: 162.
33. Barbara Cynthia Fisher (2014) The Benefits of Cognitive Stimulation or Training/Rehabilitation upon Brain Function as an Efficacious Treatment for Diagnosed Dementia or Mild Cognitive Decline. J Alzheimers Dis Parkinsonism 4: 161.
34. Faris Yaghmoor, Ahmed Noorsaeed, Samar Alsaggaf, Waleed Aljohani, Henrieta Scholtzova, et al. (2014) The Role of TREM2 in Alzheimer's Disease and Other Neurological Disorders. J Alzheimers Dis Parkinsonism 4: 160.
35. Tsuyoshi Miyaoka, Junya Tsukada, Soichi Mizuno, Ryoji Nishimura, Yasushi Inami, et al. (2014) Effect of Donepezil on Sleep and Activity in Alzheimer's Disease: Actigraphic and Polysomnographic Assessment. J Alzheimers Dis Parkinsonism 4: 157.
36. Martha F Hanby, Michelle Barraclough, Shane McKie, Neal Hinvest, Kathryn McDonald, et al. (2014) Emotional and Cognitive Processing Deficits in People with Parkinson's Disease and Apathy. J Alzheimers Dis Parkinsonism 4: 156.
37. Carlos Henrique Ferreira Camargo, Henrique Alvaro Hoffmann, Jissa Jeanete Luciano, Marcelo Rezende Young Blood, Marcelo Derbli Schafranski, et al. (2014) Orthostatic Hypotension and its Relationship to the Clinical Course of Patients with Parkinson's Disease. J Alzheimers Dis Parkinsonism 4: 155.
38. Jacques Hugon, Franccedilois MoutonLiger, Julien Dumurgier, Pauline Lapalus, Magali Preacutevocirct, et al. (2014) Involvement of PKR in Alzheimer's Disease. J Alzheimers Dis Parkinsonism 4: 154.
39. Garth F Hall (2014) Report from the Tau Front: Cantoblanco 2013. J Alzheimers Dis Parkinsonism 4: e133.
40. Moretti DV, Paternicogrove D, Binetti G, Zanetti O, Frisoni GB (2014) Impairment of the Posterior Part of the Mirror Neurons System in Alzheimer's Disease: Evidence from EEG Biomarkers. J Alzheimers Dis Parkinsonism 4: 153.
41. Andrew Tsai, Michael MalekAhmadi, Vickram Kahlon, Marwan N Sabbagh (2014) Differences in Cerebrospinal Fluid Biomarkers between Clinically Diagnosed Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease. J Alzheimers Dis Parkinsonism 4: 150.
42. Hanaa L Sadek, Sayedah F Almohari, Waleed M Renno (2014) The Inflammatory Cytokines in the Pathogenesis of Parkinson's Disease. J Alzheimers Dis Parkinsonism 4:148.
43. Maria Elisa de Oliveira Lanna, Maria Lucia Vellutini Pimentel, Sergio Augusto Pereira Novis (2014) Diabetes Effects in Alzheimer Disease: The Interactive Role of Insulin and A β Peptide. J Alzheimers Dis Parkinsonism 4: 151.
44. David Truswell (2014) Black, Asian and Minority Ethnic Communities and Dementia – Where Are We Now?. J Alzheimers Dis Parkinsonism 4: 152.
45. Hansotto Reiber, Peter Lange, Inga Zerr (2014) Neurochemical Dementia Diagnostics – Interlaboratory Variation of Analysis, Reference Ranges and Interpretations. J Alzheimers Dis Parkinsonism 4: 147.
46. Florindo Stella, (2014) Neuropsychiatric Symptoms in Alzheimer's disease Patients: Improving the Diagnosis. J Alzheimers Dis Parkinsonism 4: 146.
47. Pierre A. Denis (2014) The Continuum of Metabolic Stress According to the Gas Model of Alzheimer's disease. J Alzheimers Dis Parkinsonism 4: 149.
48. Mitchell Clionsky, Emily Clionsky (2014) Dementia Screening: Saying No to the USPSTF and Yes to Brief Cognitive Evaluation. J Alzheimers Dis Parkinsonism 4: e132.
49. Shokouhi S, Claassen D, Riddle WR (2014) Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. J Alzheimers Dis Parkinsonism 4: 143.
50. Deacon RMJ (2014) A Novel Approach to Discovering Treatments for Alzheimer's Disease. J Alzheimers Dis Parkinsonism 4: 142.
51. Frank O Bastian (2014) Cross-Roads in Research on Neurodegenerative Diseases. J Alzheimers Dis Parkinsonism 4: 141.

Research & Reviews: Journal of Medical and Health Sciences

52. Abraham Lieberman, Narayanan Krishnamurthi, Rohit Dhall, Naomi Salins, Pan D, et al. (2014) Comparison of Parkinson Disease Patients Who Fell Once with Patients Who Fell More than Once (Recurrent Fallers). *J Alzheimers Dis Parkinsonism* 4: 140.
53. Tetsumori Yamashima, Arumugam Mathivanan, Maryia Y. Dazortsava, Shota Sakai, Shota Kurimoto, et al. (2014) Calpain-Mediated Hsp70.1 Cleavage in Monkey CA1 after Ischemia Induces Similar 'Lysosomal Vesiculosis' to Alzheimer Neurons. *J Alzheimers Dis Parkinsonism* 4: 139.
54. Aaron Block, A. Ranjitha Dhanasekaran, Md. Mahiuddin Ahmed, Katheleen J Gardiner (2014) Abnormal Protein Profiles in Hippocampus of Mouse Models of Down Syndrome: Similarities with Alzheimers Disease. *J Alzheimers Dis Parkinsonism* 4: 138.
55. Mark H Sundman, Eric E Hall, Nankuei Chen (2014) Examining the Relationship between Head Trauma and Neurodegenerative Disease: A Review of Epidemiology, Pathology and Neuroimaging Techniques. *J Alzheimers Dis Parkinsonism* 4: 137.
56. Kurt A Jellinger (2014) Neuropathology of Dementia Disorders. *J Alzheimers Dis Parkinsonism* 4: 135.
57. Helmut Barz, Ulrich Barz, Almut Schreiber (2014) Neuronal Impulse Theory and Alzheimer's Disease. *J Alzheimers Dis Parkinsonism* 4: 134.
58. Julien SaintPol, Pietra Candela, Laurence Fenart, Fabien Gosselet (2013) The LXR/RXR Approaches in Alzheimer's Disease: Is the Blood-Brain Barrier the Forgotten Partner?. *J Alzheimers Dis Parkinsonism* 3: e131.
59. Kebreten F Manaye, William Rebeck G (2013) Possible APOE Genotype and Sex Dependent Effects of 17- α - estradiol on Alzheimers Disease Pathology. *J Alzheimers Dis Parkinsonism* 3: e130.
60. Jinichi Ito, Jiansheng Gong, Makoto Michikawa (2014) Oxidative Stress and FGF-1 Release from Astrocytes. *J Alzheimers Dis Parkinsonism* 4: 133.
61. Ashraf Virmani, Luigi Pinto, Otto Bauermann, Saf Zerelli, Zbigniew Binienda, et al. (2014) Neuronal Carnitine Palmitoyl Transferase1c in the Central Nervous System: Current Visions and Perspectives. *J Alzheimers Dis Parkinsonism* 4: 132.
62. Keith A Wesnes, David J Burn (2014) Compromised Object Pattern Separation Performance in Parkinson's Disease Suggests Dentate Gyrus Neurogenesis may be compromised in the Condition. *J Alzheimers Dis Parkinsonism* 4: 131.
63. Fabiano Henrique Rodrigues Soares, Gleidson Mendes Reboucas, Polyana Figueiredo Fernandes Lopes, Thiago Renee Felipe, Joao Carlos Lopes Bezerra, et. al. (2013) Measures of Heart Rate Variability in Patients with Idiopathic Parkinson's disease. *J Alzheimers Dis Parkinsonism* 3: 130.
64. Benjamin Schmitt, Ingo von Both, Catherine E Amara, Andreas Schulze (2013) Quantitative Assessment of Metabolic Changes in the Developing Brain of C57BL/6 Mice by In Vivo Proton Magnetic Resonance Spectroscopy. *J Alzheimers Dis Parkinsonism* 3: 129.
65. Sarah Lee, Ming Tong, Steven Hang, Chetram Deochand, Suzanne de la Monte, et al. (2013) CSF and Brain Indices of Insulin Resistance, Oxidative Stress and Neuro-Inflammation in Early versus Late Alzheimer's Disease. *J Alzheimers Dis Parkinsonism* 3: 128.
66. Danielle Meola, Zhi Huang, John M Petitto (2013) Selective Neuronal and Brain Regional Expression of IL-2 in IL2P 8-GFP Transgenic Mice: Relation to Sensorimotor Gating. *J Alzheimers Dis Parkinsonism* 3: 127.
67. Ryan T Pitman, Jason T Fong, Amanda L Stone, Joseph T Devito, Neelu Puri, et al. (2013) FTO Knockdown Decreases Phosphorylation of Tau in Neuronal Cells; A Potential Model Implicating the Association of FTO with Alzheimer's Disease. *J Alzheimers Dis Parkinsonism* 3: 125.
68. Rodrigo D Perea, Rebecca C Rada, Jessica Wilson, Eric D Vidoni, Jill K Morris, et al. (2013) A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease. *J Alzheimers Dis Parkinsonism* 3: 123.
69. Fabian Fernandez, Jamie O Edgin (2013) Poor Sleep as a Precursor to Cognitive Decline in Down Syndrome: A Hypothesis. *J Alzheimers Dis Parkinsonism* 3: 124.
70. Amanda Pennington, Vasyli Sava, Shijie Song, Niketa Patel, Juan Sanchez Ramos, et al. (2013) Direct Actions of Granulocyte-Colony Stimulating Factor on Human Neuronal and Monocytic Cell Lines. *J Alzheimers Dis Parkinsonism* 3: 121.

Research & Reviews: Journal of Medical and Health Sciences

71. C Douglas Simmons (2015) Responsiveness of the Canadian Occupational Performance Measure for Adults with ABI. *Int J Phys Med Rehabil* 3: 267.
72. Yamamoto S, Katsuhira J, Miura N (2015) Gait Change Using an Ankle-Foot Orthosis with an Oil Damper in a Stroke Patient with Hyperextension of the Knee Joint in Late Stance. *Int J Phys Med Rehabil* 3: 262.
73. Dali Yin, Konstantin V Slavin (2015) A Review of Neuromodulation in the Neurorehabilitation. *Int J Neurorehabilitation Eng* 2: 151.
74. Nafeez Syed, Abhisek Biswas, Nazia Hanifa, Parameswaran RV, Padma Sundaram, et al. (2015) Bilateral Versus Unilateral Upper Extremity Training on Upper Limb Motor Activity in Hemiplegia. *Int J Neurorehabilitation Eng* 2: 145.
75. Rohit Singh, Howard Stringer, Teya Drew, Christopher Evans, Richard Spencer Jones (2015) Swimming Breaststroke after Total Hip Replacement; Are We Sending the Correct Message. *J Arthritis* 4: 147.
76. G.Tamizharasi, S.Kathiresan (2013) Four Stroke Diesel Engine's Surface Ignition using Ethanol. *IJAREEIE*
77. Razvodovsky YE (2015) The Differential Effects of Beverage Type on Stroke Mortality. *J Clin Exp Cardiol* 6: 359.
78. Yarovsky N, Eran A, Telman G (2015) Prompt Recanalization of Basilar Artery (Lazarus Effect) in Patient with Acute Ischemic Cardioembolic Stroke in Spite of Relatively Late Start of Fibrinolytic Therapy. *J Vasc Med Surg* 3: 179.
79. Kleinman JT, Elahi FM, Ali LK, Hinman JD (2015) Locked Out: Basilar Dependent Cerebral Circulation in the Setting of Acute Stroke. *J Neurol Disord* 3: i108.
80. Susanne Fonville, Anouk C van Dijk, Taihra Zadi, Evita G van den Herik, Hester F Lingsma, et al. (2015) Newly-Diagnosed Disturbed Glucose Metabolism is Associated with Atherosclerosis in Patients with Transient Ischemic Attack or Ischemic Stroke. *J Diabetes Metab* 6: 496.
81. Koichiro Matsuo, Michio Yokoyama, Marlis GonzalezFernandez, Eiichi Saitoh, Hitoshi Kagaya, et al. (2015) Effects of Food Consistencies and Mastication on Bolus Transport and Swallow Initiation in Individuals with Hemispheric Stroke. *J Neurol Neurophysiol*, 6: 269.
82. Ahmad Kabir Usman, Mahmood Hussain Shah (2013) Strengthening E-Banking security using Keystroke Dynamics. *JIBC*
83. Marlene Rosa (2015) Co-contraction Role on Human Motor Control. A Neural Basis. *J Nov Physiother* 5: 248.
84. Roche N, Geiger M, Marcieca P, Robertson J, Zory R, et al. (2015) Improvement in the Gait Pattern of Chronic Stroke Patients following Repetitive Multifocal Botulinum Toxin Injections: An Observational Study. *Int J Phys Med Rehabil* 3: 249.
85. Mandi D Germain, Samadoulougou K Andreacute, Yameacuteogo R Aristide, Millogo RC Georges, Naiumlbeacute D Temoua, et al. (2015) Non Valvular Atrial Fibrillation Related Ischaemic Stroke at the Teaching Hospital of Yalgado Ouédraogo, Burkina Faso. *J Vasc Med Surg* 3: 171.
86. Dimitrios Theofanidis (2015) From Apoplexy to Brain Attack, a Historical Perspective on Stroke to Date. *J Nurs Care* 4: e121.
87. Raphaely Beer Noa, Katzleurer Michal (2014) The Association between Cardiac Autonomic Control System and Motor Performance among Patients Post Stroke: Review of the Literature. *Int J Neurorehabilitation Eng* 1: 136.
88. Santoshi Billakota, Larry B. Goldstein (2015) Monocular Diplopia Associated with a Midbrain Stroke. *J Cardiovasc Dis Diagn* 3: 184.
89. Carsten M. Klingner, Stefan Brodoehl, Christian Hohenstein, Johannes Winning, Lars Kummer, et al. (2015) A Case with 7 Min Door-To-Needle-Time and an Outline of Ultrarapid Stroke Management. *Brain Disord Ther* 4: 153.
90. Zuila Maria de Figueiredo Carvalho, Joyce Minaacute Albuquerque Coelho, Raelly Ramos Campos, Deyse Cardoso de Oliveira, Winner Gomes Machado, et al. (2014) Use of the Tinetti Index to Assess Fall Risk in Patients with Sequelae of Stroke. *Int J Phys Med Rehabil* 2: 243.
91. Jill Hutton, George J Hutton (2014) Congenital Rubella with Autism and Evidence of a Remote Stroke. *J Vaccines Vaccin* 5: 258.
92. Surajit Sarkar (2014) Protein Aggregation in Neurodegenerative Disorders: A Cause or Consequence?. *Adv Tech Biol Med* e105.

Research & Reviews: Journal of Medical and Health Sciences

93. Neeti Sharmabr nbsp (2014) Free Radicals, Antioxidants and Disease. Biol Med (Aligarh) 6: 214.
94. Kurt A Jellinger (2014) Neuropathology of Dementia Disorders. J Alzheimers Dis Parkinsonism 4: 135.
95. Haque A, Alam Q, Alam MZ, Kamal MA (2013) Global Current Trends in Drug Designing for Management of Type-2 Diabetes and Neurodegenerative Disorders. Drug Des 2: e120.
96. Renu Yadav, S Idiyasan Chanu, Kritika Raj, Surajit Sarkar (2013) Rise and Fall of Reactive Oxygen Species (ROS): Implications in Aging and Neurodegenerative Disorders. Cell Dev Biol 1: e122.
97. Raafat KM (2013) Exploration of the Protective Effects of Some Natural Compounds against Neurodegeneration Exploiting Glycine Receptors in vivo Model. Nat Prod Chem Res 1: 113.
98. Rodrigo D Perea, Rebecca C Rada, Jessica Wilson, Eric D Vidoni, Jill K Morris, et al. (2013) A Comparative White Matter Study with Parkinson's disease, Parkinson's Disease with Dementia and Alzheimer's Disease. J Alzheimers Dis Parkinsonism 3: 123.
99. Yuri L Lyubchenko (2013) Nanoimaging for Molecular Pharmaceuticals of Alzheimer's and other Neurodegenerative Disorders. J Mol Pharm Org Process Res 1: e107.
100. Jin Jun Lu, Nae J Dun (2013) Neurodegenerative Disorders and Prionopathies. J Neurol Neurophysiol 4: e113.
101. Yoko Ozawa, Mamoru Kamoshita, Toshio Narimatsu, Norimitsu Ban, Eriko Toda, et al. (2013) Neuroinflammation and Neurodegenerative Disorders of the Retina. Endocrinol Metab Syndr 2: 111.
102. Marina S Gorbatyuk, Oleg S Gorbatyuk (2013) The Molecular Chaperone GRP78/BiP as a Therapeutic Target for Neurodegenerative Disorders: A Mini Review. J Genet Syndr Gene Ther 4: 128.
103. Surajit Sarkar, M Dhruba Singh, Renu Yadav, S Idiyasan Chanu (2012) Flying with Flies: Decoding Human Neurodegenerative Disorders in Drosophila. Cell Dev Biol 1: e112.
104. Salima Douichene, Noureddine Djebli, Moussa Ahmed, Kheira Zerrouki (2012) Neuroprotective Effect of Curcumin with a Fixator of Absorption against both Aluminium Neurotoxicity and Alzheimer's Disease (Experimental Studies in Mice). J Alzheimers Dis Parkinsonism 2: 107.